Zhejiang Haisen Pharmaceutical Co., Ltd. (SHE:001367)
23.60
-0.58 (-2.40%)
Feb 2, 2026, 4:00 PM EST
SHE:001367 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 509.37 | 470.54 | 396.28 | 421.14 | 386.79 | 283.41 |
Other Revenue | 0.97 | 0.97 | 1.17 | 1.64 | 2.19 | 1.39 |
| 510.33 | 471.51 | 397.45 | 422.78 | 388.98 | 284.8 | |
Revenue Growth (YoY) | 17.50% | 18.63% | -5.99% | 8.69% | 36.58% | 6.94% |
Cost of Revenue | 289.55 | 281.91 | 237.4 | 266.52 | 236.12 | 173.83 |
Gross Profit | 220.79 | 189.6 | 160.05 | 156.26 | 152.87 | 110.97 |
Selling, General & Admin | 50.64 | 40.65 | 35.72 | 32.25 | 32.94 | 27.19 |
Research & Development | 38.11 | 27.78 | 18.84 | 15.77 | 12.07 | 10.83 |
Other Operating Expenses | 6.81 | 4.36 | 4.16 | 2.13 | 3.11 | 2.59 |
Operating Expenses | 97.03 | 72.88 | 59.15 | 51.24 | 47.85 | 39.97 |
Operating Income | 123.76 | 116.72 | 100.9 | 105.02 | 105.02 | 71 |
Interest Expense | -0.35 | -0.37 | -0.03 | -0.07 | -0.1 | - |
Interest & Investment Income | 11.61 | 18.41 | 15.62 | 3.55 | 2.25 | 4.22 |
Currency Exchange Gain (Loss) | 3.32 | 3.32 | 0.87 | 8.37 | -2.17 | -3.76 |
Other Non Operating Income (Expenses) | 0.02 | -0.24 | -0.19 | 0.05 | -0.4 | -0.3 |
EBT Excluding Unusual Items | 138.36 | 137.85 | 117.17 | 116.93 | 104.59 | 71.17 |
Gain (Loss) on Sale of Investments | - | - | - | -3.85 | 0.74 | - |
Gain (Loss) on Sale of Assets | -0.27 | - | -0.24 | - | - | - |
Asset Writedown | -1.04 | -1.23 | -0.96 | -1.21 | -0.67 | -0.24 |
Other Unusual Items | 6.78 | 5.11 | 4.71 | 11.91 | 3.86 | 2.64 |
Pretax Income | 143.89 | 141.79 | 120.68 | 123.78 | 108.52 | 73.57 |
Income Tax Expense | 20.08 | 19.23 | 16.01 | 16.19 | 14.52 | 10.75 |
Net Income | 123.82 | 122.56 | 104.67 | 107.59 | 94 | 62.83 |
Net Income to Common | 123.82 | 122.56 | 104.67 | 107.59 | 94 | 62.83 |
Net Income Growth | 3.45% | 17.09% | -2.72% | 14.46% | 49.62% | -8.89% |
Shares Outstanding (Basic) | 148 | 149 | 137 | 112 | 112 | 112 |
Shares Outstanding (Diluted) | 152 | 150 | 137 | 112 | 112 | 112 |
Shares Change (YoY) | 1.21% | 9.35% | 22.74% | -0.02% | - | -0.16% |
EPS (Basic) | 0.83 | 0.82 | 0.76 | 0.96 | 0.84 | 0.56 |
EPS (Diluted) | 0.82 | 0.82 | 0.76 | 0.96 | 0.84 | 0.56 |
EPS Growth | 2.21% | 7.09% | -20.74% | 14.68% | 49.60% | -8.89% |
Free Cash Flow | 2.66 | 102.41 | 23.17 | 54.76 | 73.72 | 55.48 |
Free Cash Flow Per Share | 0.02 | 0.68 | 0.17 | 0.49 | 0.66 | 0.50 |
Dividend Per Share | 0.115 | 0.115 | 0.228 | - | - | - |
Dividend Growth | -49.65% | -49.65% | - | - | - | - |
Gross Margin | 43.26% | 40.21% | 40.27% | 36.96% | 39.30% | 38.96% |
Operating Margin | 24.25% | 24.75% | 25.39% | 24.84% | 27.00% | 24.93% |
Profit Margin | 24.26% | 25.99% | 26.33% | 25.45% | 24.16% | 22.06% |
Free Cash Flow Margin | 0.52% | 21.72% | 5.83% | 12.95% | 18.95% | 19.48% |
EBITDA | 140.62 | 131.76 | 113.52 | 118.59 | 117.37 | 81.64 |
EBITDA Margin | 27.56% | 27.94% | 28.56% | 28.05% | 30.17% | 28.67% |
D&A For EBITDA | 16.86 | 15.04 | 12.62 | 13.56 | 12.35 | 10.64 |
EBIT | 123.76 | 116.72 | 100.9 | 105.02 | 105.02 | 71 |
EBIT Margin | 24.25% | 24.75% | 25.39% | 24.84% | 27.00% | 24.93% |
Effective Tax Rate | 13.95% | 13.56% | 13.26% | 13.08% | 13.38% | 14.61% |
Revenue as Reported | 510.33 | 471.51 | 397.45 | 422.78 | 388.98 | 284.8 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.